Lurbinectedin sensitizes PD-L1 blockade therapy by activating STING-IFN signaling in small-cell lung cancer.
Chakraborty S, Sen U, Ventura K, Jethalia V, Coleman C, Sridhar S, Banerjee A, Ozakinci H, Mahendravarman Y, Snioch K, de Stanchina E, Shields MD, Tomalin LE, Demircioglu D, Boyle TA, Tocheva A, Hasson D, Sen T.
Chakraborty S, et al.
Cell Rep Med. 2024 Dec 17;5(12):101852. doi: 10.1016/j.xcrm.2024.101852. Epub 2024 Dec 9.
Cell Rep Med. 2024.
PMID: 39657664